Sanofi on LinkedIn: Press Release: Sanofi announces agreement for potential first-in-class… | 26 comments
Sanofi on LinkedIn: We aim to be an industry-leading company in Immunology. We are announcing… | 17 comments
Sanofi on X: "#SanofiActs against #COVID19 Read more on our latest collaboration with @TranslateBio, investigating multiple candidates, with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development. https://t.co/C8B5bsy7DH
![Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery – Atomwise Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery – Atomwise](https://www.atomwise.com/wp-content/uploads/2022/08/atomwise-signs-strategic-collaboration-sanofi-pr-1200x630-1.png)
Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery – Atomwise
![Sanofi в X: „Press release: #Sanofi announces that it will acquire @ProteinSciences https://t.co/Uvipij6Bkr https://t.co/FoBXWy5xe4“ / X Sanofi в X: „Press release: #Sanofi announces that it will acquire @ProteinSciences https://t.co/Uvipij6Bkr https://t.co/FoBXWy5xe4“ / X](https://pbs.twimg.com/media/DEhiniWXcAIbYeM.jpg)
Sanofi в X: „Press release: #Sanofi announces that it will acquire @ProteinSciences https://t.co/Uvipij6Bkr https://t.co/FoBXWy5xe4“ / X
![SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate](https://mma.prnewswire.com/media/2144614/Jaeyong_Ahn_CEO_of_SK_bioscience__left__Thomas_Triomphe_Head_of_Vaccines_GBU_at_Sanofi__right.jpg?p=facebook)
SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate
![PRESS RELEASE: Sanofi Partnering With Leading Academic Cooperative Groups To Study Amcenestrant In The Adjuvant Setting For Patients With Estrogen Receptor Positive Breast Cancer 2023 - EORTC PRESS RELEASE: Sanofi Partnering With Leading Academic Cooperative Groups To Study Amcenestrant In The Adjuvant Setting For Patients With Estrogen Receptor Positive Breast Cancer 2023 - EORTC](http://www.eortc.org/app/uploads/2021/06/Sanofi_press-release.jpg)
PRESS RELEASE: Sanofi Partnering With Leading Academic Cooperative Groups To Study Amcenestrant In The Adjuvant Setting For Patients With Estrogen Receptor Positive Breast Cancer 2023 - EORTC
Nancy Whiting on LinkedIn: Recludix Pharma Enters into a Strategic Collaboration with Sanofi to… | 20 comments
PDF - Paris2024-Press Release - Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris.pdf
![Paul Hudson, Chief Executive Officer of Sanofi speaks to the press at French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile, near Lyon, central France, on June 16, 2020. The visit comes Paul Hudson, Chief Executive Officer of Sanofi speaks to the press at French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile, near Lyon, central France, on June 16, 2020. The visit comes](https://c8.alamy.com/comp/2DFAY2T/paul-hudson-chief-executive-officer-of-sanofi-speaks-to-the-press-at-french-drugmakers-vaccine-unit-sanofi-pasteur-plant-in-marcy-letoile-near-lyon-central-france-on-june-16-2020-the-visit-comes-after-rival-pharmaceutical-company-this-weekend-announced-a-deal-to-supply-400-million-vaccine-doses-to-eu-countries-including-france-photo-by-bonypoolabacapresscom-2DFAY2T.jpg)
Paul Hudson, Chief Executive Officer of Sanofi speaks to the press at French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile, near Lyon, central France, on June 16, 2020. The visit comes
![Sanofi on Twitter: "We're pleased to announce the acquisition of Origimm, an Austrian #biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing #skindiseases, such as # Sanofi on Twitter: "We're pleased to announce the acquisition of Origimm, an Austrian #biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing #skindiseases, such as #](https://pbs.twimg.com/media/FFgEnuYX0AMAFyN.png:large)
Sanofi on Twitter: "We're pleased to announce the acquisition of Origimm, an Austrian #biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing #skindiseases, such as #
![Flatiron Health Embarks on Strategic Collaboration with Sanofi to Make Clinical Trials More Efficient by Streamlining Data Acquisition at the Point of Care | BioSpace Flatiron Health Embarks on Strategic Collaboration with Sanofi to Make Clinical Trials More Efficient by Streamlining Data Acquisition at the Point of Care | BioSpace](https://mms.businesswire.com/media/20230501005091/en/1778081/4/Press-Featured-Image-SanofixFlatiron.jpg)